Related Experiment Video
Updated: May 25, 2025
04:46
The Quantification of Injectability by Mechanical Testing
Published on: May 13, 2020
7.8K
[Experimental study on injection completion rate and performance for needle-free insulin injection].
Summary
Needle-free injection technology offers improved drug delivery. Optimizing nozzle diameter enhances injection completion rates and extends drug efficacy, surpassing traditional methods.
Area of Science:
- Biomedical Engineering
- Pharmacology
Context:
- Needle-free injection is a novel drug delivery method using high-speed micro-jets.
- Existing research lacks comprehensive understanding of its drug dispersion and performance.
Purpose:
- To identify critical parameters influencing needle-free injection.
- To evaluate the impact of these parameters on injection performance and drug effect.
Summary:
- Mouse experiments revealed nozzle diameter as the most critical parameter for jet characteristics.
- Injection completion rates improved with larger nozzle diameters (89.7% for 0.14 mm, 95.8% for 0.25 mm).
- Needle-free insulin delivery demonstrated a prolonged therapeutic effect (>120 min) compared to needle-syringe methods.
Impact:
- Findings offer crucial insights for optimizing air-powered needle-free injector design.
- Results support the broader application of needle-free injection technology in drug delivery.
Related Concept Videos
01:27Insulin Formulations: Types and Delivery
160
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
160
01:16Insulin: Dosing Regimen and Adverse Effects
137
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
137